{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T16:33:17Z","timestamp":1690821197822},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T00:00:00Z","timestamp":1313452800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1038\/bjc.2011.316","type":"journal-article","created":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T20:09:16Z","timestamp":1313525356000},"page":"897-902","source":"Crossref","is-referenced-by-count":1,"title":["Paclitaxel\u2013ifosfamide\u2013carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours"],"prefix":"10.1038","volume":"105","author":[{"given":"C","family":"Kosmas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Vorgias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Tsakonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Politis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Daladimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Panagiotidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Papachrysanthou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Moschovis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Kalinoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Tsavaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Karabelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,16]]},"reference":[{"key":"BFbjc2011316_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<561::AID-CNCR19>3.0.CO;2-#","volume":"82","author":"CA Bunnell","year":"1998","unstructured":"Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, Shulman LN (1998) A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer 82: 561\u2013566","journal-title":"Cancer"},{"key":"BFbjc2011316_CR2","volume-title":"The Analysis of Binary Data","author":"DR Cox","year":"1970","unstructured":"Cox DR (1970) The Analysis of Binary Data. Methuen: London, UK"},{"key":"BFbjc2011316_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1006\/gyno.2001.6256","volume":"83","author":"J Curtin","year":"2001","unstructured":"Curtin J, Blessing JA, Soper JT, DeGeest K (2001) Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 83: 268\u2013270","journal-title":"Gynecol Oncol"},{"key":"BFbjc2011316_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1006\/gyno.2002.6645","volume":"85","author":"LR Duska","year":"2002","unstructured":"Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF (2002) Paclitaxel and platinum chemotherapy for malignant mixed m\u00fcllerian tumors of the ovary. Gynecol Oncol 85: 459\u2013463","journal-title":"Gynecol Oncol"},{"key":"BFbjc2011316_CR5","unstructured":"Hensley ML (2006) Uterine sarcomas and carcinosarcomas: advances for advanced disease and updates on adjuvant therapy. ASCO Educational Book 301\u2013304"},{"key":"BFbjc2011316_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1200\/JCO.2006.06.4907","volume":"25","author":"HD Homesley","year":"2007","unstructured":"Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, Ueland FR (2007) Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 25: 526\u2013531","journal-title":"J Clin Oncol"},{"key":"BFbjc2011316_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ygyno.2007.08.084","volume":"108","author":"PJ Hoskins","year":"2008","unstructured":"Hoskins PJ, Le N, Ellard S, Lee U, Martin LA, Swenerton KD, Tinker AV; British Columbia Cancer Agency (2008) Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol 108: 58\u201362","journal-title":"Gynecol Oncol"},{"key":"BFbjc2011316_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1959","unstructured":"Kaplan EL, Meier P (1959) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"BFbjc2011316_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10147-008-0767-1","volume":"13","author":"W Kawaguchi","year":"2008","unstructured":"Kawaguchi W, Itamochi H, Kigawa J, Kanamori Y, Oishi T, Shimada M, Sato S, Sato S, Terakawa N (2008) Chemotherapy consisting of paclitaxel and carboplatin benefits a patient with malignant mixed m\u00fcllerian tumor of the fallopian tube. Int J Clin Oncol 13: 461\u2013463","journal-title":"Int J Clin Oncol"},{"key":"BFbjc2011316_CR10","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/sj.bjc.6605305","volume":"101","author":"C Kosmas","year":"2009","unstructured":"Kosmas C, Mylonakis N, Tsakonas G, Vorgias G, Karvounis N, Tsavaris N, Daladimos T, Kalinoglou N, Malamos N, Akrivos T, Karabelis A (2009) Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and\/or metastatic cervical cancer. Br J Cancer 101: 1059\u20131065","journal-title":"Br J Cancer"},{"key":"BFbjc2011316_CR11","first-page":"25","volume":"6","author":"JE Liebmann","year":"2004","unstructured":"Liebmann JE, Fisher J, Teague D (2004) Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6: 25\u201331","journal-title":"Oncol Res"},{"key":"BFbjc2011316_CR12","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/0006-2952(89)90419-X","volume":"38","author":"MJ Lind","year":"1989","unstructured":"Lind MJ, McGowan AT, Hadfield JA, Thatcher N, Crowther D, Fox BW (1989) The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 38: 1835\u20131840","journal-title":"Biochem Pharmacol"},{"key":"BFbjc2011316_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207\u2013214","journal-title":"Cancer"},{"key":"BFbjc2011316_CR14","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E","volume":"52","author":"GA Omura","year":"1983","unstructured":"Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, Zaino RJ (1983) A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52: 626\u2013632","journal-title":"Cancer"},{"key":"BFbjc2011316_CR15","first-page":"83","volume":"15","author":"RJ Parker","year":"1993","unstructured":"Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E (1993) Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr 15: 83\u201388","journal-title":"J Natl Cancer Inst Monogr"},{"key":"BFbjc2011316_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ygyno.2008.05.017","volume":"110","author":"D Pectasides","year":"2008","unstructured":"Pectasides D, Pectasides E, Papaxoinis G, Xiros N, Sykiotis C, Papachristodoulou A, Tountas N, Panayiotides J, Economopoulos T (2008) Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution. Gynecol Oncol 110: 299\u2013303","journal-title":"Gynecol Oncol"},{"key":"BFbjc2011316_CR17","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1200\/JCO.2009.26.8326","volume":"28","author":"MA Powell","year":"2010","unstructured":"Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, Miller BE, Susumu N, Ueland FR (2010) Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol 28: 2727\u20132731","journal-title":"J Clin Oncol"},{"key":"BFbjc2011316_CR18","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1200\/jco.2007.25.18_suppl.5589","volume":"25","author":"LM Ramondetta","year":"2007","unstructured":"Ramondetta LM, Lacour RA, Euscher ED, Iyer RB, Atkinson EN, Gano JB, Milam MR, Ramirez PT, Levenback CF, Burke TW (2007) A phase II multicenter trial of paclitaxel and carboplatin in women with advanced or recurrent malignant mixed m\u00fcllerian tumors (MMMT) of the uterus. J Clin Oncol 25: 18S (abstr 5589)","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"BFbjc2011316_CR19","first-page":"90","volume":"22","author":"E Reed","year":"1995","unstructured":"Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M (1995) Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 22 (Suppl 6): 90\u201396","journal-title":"Semin Oncol"},{"key":"BFbjc2011316_CR20","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1200\/JCO.1993.11.10.2010","volume":"11","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC (1993) Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010\u20132020","journal-title":"J Clin Oncol"},{"key":"BFbjc2011316_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1\u201310","journal-title":"Control Clin Trials"},{"key":"BFbjc2011316_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1006\/gyno.2000.5956","volume":"79","author":"AS Sit","year":"2000","unstructured":"Sit AS, Price FV, Kelley JL, Comerci JT, Kunschner AJ, Kanbour-Shakir A, Edwards RP (2000) Chemotherapy for malignant mixed M\u00fcllerian tumors of the ovary. Gynecol Oncol 79: 196\u2013200","journal-title":"Gynecol Oncol"},{"key":"BFbjc2011316_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0002-9378(89)90507-3","volume":"161","author":"G Sutton","year":"1989","unstructured":"Sutton G, Blessing JA, Rosenshine N, Photopulos G, DiSaia PJ (1989) Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 161: 309\u2013312","journal-title":"Am J Obstet Gynecol"},{"key":"BFbjc2011316_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1006\/gyno.2000.6001","volume":"79","author":"G Sutton","year":"2000","unstructured":"Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, Lentz SS, Sorosky J, Hsiu JG (2000) A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol. 79: 147\u2013153","journal-title":"Gynecol Oncol."},{"key":"BFbjc2011316_CR25","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ygyno.2004.11.022","volume":"96","author":"G Sutton","year":"2005","unstructured":"Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H (2005) Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 96: 630\u2013634","journal-title":"Gynecol Oncol"},{"key":"BFbjc2011316_CR26","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1200\/JCO.1991.9.11.1962","volume":"9","author":"JT Thigpen","year":"1991","unstructured":"Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E (1991) Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 9: 1962\u20131966","journal-title":"J Clin Oncol"},{"key":"BFbjc2011316_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ygyno.2004.05.048","volume":"94","author":"M Toyoshima","year":"2004","unstructured":"Toyoshima M, Akahira J, Matsunaga G, Niikura H, Ito K, Yaegashi N, Tase T (2004) Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol 94: 774\u2013778","journal-title":"Gynecol Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2011316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011316","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:02:49Z","timestamp":1684414969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2011316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,16]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["BFbjc2011316"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2011.316","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,16]]}}}